Articles By Jack Cush, MD
Shingles Risk with JAK Inhibitors and Other Biologics
By Jack Cush, MD
29 July 2021
Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs.
Read Article
No Cancer Risk with TNF Inhibitors in Rheumatoid Arthritis
By Jack Cush, MD
29 July 2021
The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs).
Read Article
Combo Methotrexate and Leflunomide Safety in RA
By Jack Cush, MD
28 July 2021
Methotrexate and leflunomide (LEF) are the most widely prescribed DMARDs worldwide; yet biologic DMARDs are the newest and best selling agents for rheumatoid arthritis worldwide.
Read Article
Cardiovascular Prevention Lacking in Rheumatoid Arthritis
By Jack Cush, MD
28 July 2021
An increased cardiovascular disease (CVD) risk in rheumatoid arthritis is well known and feared but an RA cohort study suggests that preventive medication use in RA patients lags behind that seen in diabetes mellitus (DM).
Read Article
CDC Reverses Stance on Masks
By Jack Cush, MD
27 July 2021
Today the Centers for Disease Control and Prevention (CDC) said that masks should be used by those vaccinated against the coronavirus in public indoor spaces in parts of the country where the virus is surging.
Read Article
US News & World Report Ranks Best Rheumatology Hospitals
By Jack Cush, MD
27 July 2021
Medscape has published the annual U.S. News and World Reports ranking of Rheumatology Hospitals, again honoring Johns Hopkins Hospital with the top spot, with runner up status going to the Cleveland Clinic, Hospital for Special Surgery, Mayo Clinic and Brigham and Women's Hospital.
Read Article
Rheumatoid Poor Outcomes Not Linked to Comorbidity
By Jack Cush, MD
26 July 2021
Disease activity leads to poor outcomes; but does comorbidity add to this? A recent analysis suggests that while comorbidities do not affect long-term, functional outcomes, sociodemographic factors do affect outcomes in rheumatoid Arthritis (RA).
Read Article
DMARD Effects on COVID-19 Outcomes
By Jack Cush, MD
26 July 2021
Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs)
Read Article
RheumNow Podcast – World Going to Pot (7.23.2021)
By Jack Cush, MD
23 July 2021
Bicycles, Tramadol, biologics - these are but a few of my favorites things in today's broadcast. Join me as I review the news and journal articles from this past week on RheumNow.com.
Read Article
Fracture Risk with Low Dose Steroid
By Jack Cush, MD
22 July 2021
A large RA cohort analysis shows that low-dose glucocorticoid therapy in rheumatoid arthritis (RA) patients may carry an increased risk of vertebral osteoporotic (OP) fractures.
Read Article